X4 Pharmaceuticals Inc
$ 3.88
4.02%
11 Jun - close price
- Market Cap 351,812,000 USD
- Current Price $ 3.88
- High / Low $ 3.89 / 3.67
- Stock P/E N/A
- Book Value 1.79
- EPS -2.07
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -1.04 %
- 52 Week High 4.83
- 52 Week Low 1.35
About
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back diseases. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$11.75
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-03-17 | 2025-11-05 | 2025-08-08 | 2025-05-01 | 2025-03-25 | 2024-11-13 | 2024-08-08 | 2024-05-07 | 2024-03-21 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.16 | -0.22 | -0.69 | -3.47 | 0.04 | -0.2 | -0.18 | -0.07 | -0.26 | -0.1 | -0.01 | -0.33 |
| Estimated EPS | -0.2 | -0.3475 | -0.125 | -0.0883 | -3.75 | -0.1575 | -0.17 | 0.01 | -0.16 | -0.15 | -0.15 | -0.16 |
| Surprise | 0.04 | 0.1275 | -0.565 | -3.3817 | 3.79 | -0.0425 | -0.01 | -0.08 | -0.1 | 0.05 | 0.14 | -0.17 |
| Surprise Percentage | 20% | 36.6906% | -452% | -3829.7848% | 101.0667% | -26.9841% | -5.8824% | -800% | -62.5% | 33.3333% | 93.3333% | -106.25% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XFOR
2026-06-02 13:40:28
Leerink Partners has initiated coverage on X4 Pharmaceuticals (XFOR) with an "Outperform" rating and a price target of $12.00, signaling a positive outlook for the biotech company. Despite this, XFOR has a low GF Score™ of 30/100, reflecting challenges in financial strength and profitability, and recent insider selling activity raises caution. X4 Pharmaceuticals specializes in developing therapies for rare hematology diseases, with mavorixafor as its lead candidate.
2026-06-02 11:40:28
Leerink has initiated coverage on X4 Pharmaceuticals (NASDAQ: XFOR) with an outperform rating and a $12.00 price target, citing strong potential for its lead program, mavorixafor, in chronic neutropenia. The company's oral CXCR4 antagonist, already approved for WHIM syndrome, is seen as a potential blockbuster with significant upside for investors, supported by strong biologic rationale and unmet medical need. Other firms like Stifel and Guggenheim also maintain positive ratings, highlighting confidence in X4 Pharmaceuticals' pipeline and strategic direction.
2026-06-02 10:40:28
Leerink Partners has initiated coverage on X4 Pharmaceuticals (XFOR) with an Outperform rating and a $12 price target. This announcement was made on June 2, 2026, at 06:34 am EDT by MT Newswires. X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing therapies for rare diseases, particularly those involving immune system dysfunction, with its lead candidate being mavorixafor.
2026-06-01 22:39:57
X4 Pharmaceuticals (XFOR) announced inducement grants under Nasdaq Listing Rule. This news was reported by Reuters and is less than a minute read. The information is copyrighted by Thomson Reuters.
2026-06-01 16:30:00
X4 Pharmaceuticals announced inducement awards granted on May 29, 2026, to new employees under its 2019 Inducement Equity Incentive Plan, comprising options to purchase 160,000 shares of common stock. These grants, approved by X4’s Compensation Committee, comply with Nasdaq Listing Rule 5635(c)(4) and aim to attract new talent. Each option has a ten-year term, an exercise price of $4.31 per share, and a four-year vesting schedule.
2026-06-01 08:40:24
X4 Pharmaceuticals announced inducement awards of options to purchase 160,000 shares of its common stock to new employees on May 29, 2026. These grants, made under the 2019 Inducement Equity Incentive Plan and approved by the Compensation Committee, are material inducements for their employment, complying with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term with an exercise price of $4.31 per share and vest over four years.
